SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gordon, C
Right arrow Articles by Kilby, M D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gordon, C
Right arrow Articles by Kilby, M D
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome

C Gordon

Department of Rheumatology; University of Birmingham, Birmingham B15 2TT, UK

M D Kilby

Department of Fetal Medicine, University of Birmingham, Birmingham B15 2TT, UK

Systemic lupus erythematosus and antiphospholipid antibody syndrome are associated with an increased risk of intrauterine growth restriction, miscarriage, stillbirth and premature delivery. Recent advances in therapy during pregnancy have improved the outcome but there is still significant fetal and maternal morbidity and mortality. Treatment of patients failing conventional therapy during the second half of pregnancy is difficult and may be complicated by the development of preeclampsia. The addition of intravenous immunoglobulin therapy offers a low risk strategy for reducing autoantibody mediated disease and improving placental function in severely compromised, growth restricted pregnancies.

Key Words: intravenous immunoglobulin • pregnancy • systemic lupus erythematosus • antiphospholipid syndrome • therapy

Lupus, Vol. 7, No. 7, 429-433 (1998)
DOI: 10.1191/096120398678920451


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Clin Med ResHome page
J. P. Dhar and R. J. Sokol
Lupus and Pregnancy: Complex Yet Manageable
Clin. Med. Res., December 1, 2006; 4(4): 310 - 321.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
H C Horn, K Grau, and P Junker
IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome
Lupus, June 1, 2004; 13(6): 478 - 480.
[Abstract] [PDF]


Home page
CMAJHome page
J. G. Hanly
Antiphospholipid syndrome: an overview
Can. Med. Assoc. J., June 24, 2003; 168(13): 1675 - 1682.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
L. Heilmann, G.-F. v. Tempelhoff, and K. Pollow
Antiphospholipid Syndrome in Obstetrics
Clinical and Applied Thrombosis/Hemostasis, April 1, 2003; 9(2): 143 - 150.
[Abstract] [PDF]



Advertisement